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Fig.　1　Positive skin prick test in response to CFPN-PI on 
the left forearm. (a) ×1 dilution, (b) normal saline.
Dear Editor
Positive Skin Prick Test to Cefcapene
Pivoxil Hydrochloride Hydrate:
A Case Report
Cefcapene pivoxil hydrochloride hydrate (CFPN-PI)
(FlomoxⓇ, Shionogi & Co., Ltd., Osaka, Japan)1 is an
oral cephem antibiotic that exerts an antibacterial ef-
fect by inhibiting the synthesis of bacterial cell walls.
Here, we described the first case of a positive skin
prick test to CFPN-PI.
A 67-year-old Japanese man was referred to our de-
partment for performance of allergy tests. He had un-
dergone tooth extraction using local anesthesia (xylo-
caine 2% with adrenaline, xylestesinTM-A, 3M Health
Care Ltd., Tokyo, Japan) at a private dental clinic be-
cause of caries 1 month before his first visit to our de-
partment. After the treatment, he had taken a CFPN-
PI 100 mg tablet. After 30 minutes, he noticed multi-
ple wheals over his whole body with slight dyspnea.
He immediately visited the emergency department of
a general hospital and the eruption and the dyspnea
disappeared completely within a few hours with treat-
ment with intravenous drip injection of Strong-Neo-
Minophagen C. On the next day he consulted with a
dermatologist in the general hospital. A medication
allergy to CFPN-PI or local anesthetic was suspected
based on the history. In an initial physical examina-
tion in our department, no eruption was seen any-
where on his body. Laboratory data, including a com-
plete blood count and liver function test results, were
also within normal limits. A false positive was ob-
served in a lymphocyte transformation test to CFPN-
PI (stimulation index 1.6; false positive 1.6-1.7; posi-
tive1.8). Therefore, skin prick tests were performed
in an inpatient setting using a CFPN-PI tablet and
xylestesinTM-A diluted (×1, ×10, ×100) with normal sa-
line solution, respectively. The skin prick tests were
carried out using 1% histamine hydrochloride solu-
tion and normal saline as positive and negative con-
trols, respectively. After fifteen minutes, the tests
showed negative with xylestesinTM-A (×1, ×10, ×100)
and CFPN-PI solutions (×10, ×100), but positive with
a CFPN-PI solution (×1) (Fig. 1) . The same tests
were all negative in a healthy control. Therefore, we
diagnosed this case as immediate type drug allergy
due to CFPN-PI.
CFPN-PI was developed in 1997 in Japan as a
cephem antibiotic used to treat infections. It is indi-
cated for treatment of a wide range of bacterial infec-
tions, including skin, respiratory, pharyngeal tonsil,
urinary tract, gynecologic, ophthalmologic, otologic,
dental, and oral infections. 2-4 CFPN-PI is also ap-
proved for use in bacterial infections in Korea. How-
ever, to our knowledge, this report and that of
Kawada et al.1 are the only two descriptions of drug
allergy induced by CFPN-PI in the English language
literature. In Kawada et al.,1 the patient was given 100
mgday oral CFPN-PI for prevention of infection of
the thigh skin at a site at which an angioinfusion
catheter had been placed for hepatic cancer 2 days
earlier. Patch tests with CFPN-PI 10% and 1% pet
were positive, which indicated delayed type allergy.
The patient in our case showed an immediate-type al-
lergic reaction on the basis of positive skin prick test.
Therefore, this report is the first to describe a CFPN-
PI-induced immediate type drug eruption.
Oral administration of CFPN-PI is considered to be
useful and convenient for treatment of various bacte-
rial infections in an outpatient setting. In the past, he
had also used CFPN-PI several times to treat bacte-
rial infection. Therefore, the sensitization to CFPN-PI
might have occurred unconsciously. According to the
Shionogi pharmaceutical company, a frequency of
CFPN-PI-induced immediate type reaction such as ur-
ticaria and anaphylactic shock was <0.1%. However,
medical practitioners should be aware of potential al-
lergic reactions to CFPN-PI, which might occur in the
form of immediate or delayed-type adverse drug reac-
tions.
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